Drug Trial Radar · NCT00563381
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
Last checked: Nov 19, 2026Latest source record: Dec 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,376
Actual
Start
Jan 2008
Primary completion
Apr 2010
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Nov 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits. The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations. The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation. The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator. Only COPD exacerbations with onset during randomised treatment will be included in the analysis.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium bromideDrug
18 mcg/daily
SalmeterolDrug
100 mcg/daily
Placebo SalmeterolDrug
Placebo identical to Salmeterol device
Placebo TiotropiumDrug
Placebo identical to Tiotropium device
Primary outcomes
What the sponsor says the trial is designed to measure.
- First Occurrence of (Moderate or Severe) COPD ExacerbationTime frame: 52 weeks
Locations
752 sites in 25 countries. Site status is shown where the registry gives one.
205.389.1020 Boehringer Ingelheim Investigational Site
Feldbach, Austria
205.389.1010 Boehringer Ingelheim Investigational Site
Feldkirch, Austria
205.389.1003 Boehringer Ingelheim Investigational Site
Gänserndorf, Austria
205.389.1011 Boehringer Ingelheim Investigational Site
Grimmenstein/Hochegg, Austria
205.389.1005 Boehringer Ingelheim Investigational Site
Hallein, Austria
205.389.1023 Boehringer Ingelheim Investigational Site
Linz, Austria
205.389.1001 Boehringer Ingelheim Investigational Site
Mittersill, Austria
205.389.1027 Boehringer Ingelheim Investigational Site
Salzburg, Austria
205.389.1026 Boehringer Ingelheim Investigational Site
Schlüsslberg, Austria
205.389.1016 Boehringer Ingelheim Investigational Site
Spittal/Drau, Austria
205.389.1022 Boehringer Ingelheim Investigational Site
Steyr, Austria
205.389.1002 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1006 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1014 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1018 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1021 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1029 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.389.1017 Boehringer Ingelheim Investigational Site
Zwettl Stadt, Austria
205.389.1120 Boehringer Ingelheim Investigational Site
Buizingen, Belgium
205.389.1124 Boehringer Ingelheim Investigational Site
Cerexhe-Heuseux, Belgium
205.389.1116 Boehringer Ingelheim Investigational Site
Chenée (Liége), Belgium
205.389.1121 Boehringer Ingelheim Investigational Site
Dour, Belgium
205.389.1113 Boehringer Ingelheim Investigational Site
Gembloux, Belgium
205.389.1117 Boehringer Ingelheim Investigational Site
Gozée, Belgium
205.389.1126 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
205.389.1129 Boehringer Ingelheim Investigational Site
Natoye, Belgium
205.389.1130 Boehringer Ingelheim Investigational Site
Quaregnon, Belgium
205.389.1115 Boehringer Ingelheim Investigational Site
Thuillies, Belgium
205.389.1107 Boehringer Ingelheim Investigational Site
Wetteren, Belgium
205.389.3911 Boehringer Ingelheim Investigational Site
Pazardzhik, Bulgaria
205.389.3903 Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
205.389.3915 Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
205.389.3918 Boehringer Ingelheim Investigational Site
Rousse, Bulgaria
205.389.3914 Boehringer Ingelheim Investigational Site
Sliven, Bulgaria
205.389.3902 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3906 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3907 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3908 Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
205.389.3916 Boehringer Ingelheim Investigational Site
Troyan Municipality, Bulgaria
205.389.3912 Boehringer Ingelheim Investigational Site
Varna, Bulgaria
Showing 40 of 752 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.